A randomised double blind placebo controlled study was conducted to determine whether a one week course of dexamethasone could reduce the severity of bronchopulmonary dysplasia in preterm infants without compromising their adrenal function. Forty one infants with a mean birth weight of 880 g and a gestational age of 27 weeks who were ventilator dependent at 10 days of age were enrolled. At the age of 28 days pulmonary outcome was significantly better in the girls treated with dexamethasone but not in all infants. There was no difference between the groups in the long term outcome, except for a shorter duration of supplemental oxygen in dexamethasone treated female infants. After the one week dexamethasone treatment there was a significant but short lived suppression of the basal cortisol concentrations and the adrenal response to corticotrophin (ACTH). No serious side effects were observed.
In spite of improvement in the outcome of very low birthweight (VLBW) infants, bronchopulmonary dysplasia remains a major cause of long term morbidity. [1] [2] [3] Glucocorticoids are widely used for the treatment of bronchopulmonary dysplasia. This practice is based on several clinical trials, mostly with fairly small sample size, variable age and criteria for starting treatment, and variable criteria for evaluating outcome. [4] [5] [6] [7] [8] In a large international multicentre trial a one week course of dexamethasone at a constant dose of 0-6 mg/kg/day was given,9 whereas most of the others have used the dosage originally suggested by Avery et al,4 0 5 mg/kg/day for three days, with variable length of tapering. In most studies steroids were allowed after the completion of the trial drug, further complicating the evaluation of the long term prognosis.
The aim of this multicentre trial was to assess whether a one week high dose course of dexamethasone, started at the age of 10 days, improves oxygenation to allow weaning of ventilator dependent VLBW infants, whether it reduces the severity of bronchopulmonary dysplasia, and whether it is safe.
Patients and methods

PATIENTS AND STUDY DESIGN
The study was conducted at four hospitals: the Children's Hospital, University of Helsinki; Department of Paediatrics, University of Kuopio; Department of Paediatrics, University of Oulu; and Department of Paediatrics, University of Tampere. The study design was approved by the ethical committees of all participating hospitals. The entry criteria were: (a) birth weight 1500 g or less; (b) gestational age 24 weeks or more; (c) dependence on mechanical ventilation at 10 days of age; and (d) no signs of patent ductus arteriosus, sepsis, gastrointestinal bleeding, or major malformation at entry.
After informed consent was obtained from the parents, eligible infants were randomised to receive a seven day course of either dexamethasone or placebo. Clinicians and investigators were unaware of treatment assignments. Randomisation was performed in blocks of 10 for each participating hospital. The infants in the dexamethasone group received 0*5 mg/kg/day dexamethasone sodium phosphate (Oradexon, Organon) intravenously in two doses for seven days, whereas infants in the placebo group received 0 9% saline.
Before entry, after the one week treatment period, and at the age of 28 days a two hour corticotrophin (ACTH) test was performed on all study infants. Blood samples were obtained from an indwelling arterial line, by venipuncture, or by heel stick before (basal sample) and two hours after (stimulated sample) an intra- Age at start of trial drug (days) 880 (194) 27 (2) 11 (65) 5 (29) 6 (35) 4 (24) 2 (12) 9 (53) 4 (24) 2 (12) 2 (12) 14 (3) 880 (194) 27 (2) 8 (33) 3 (13) 6 (25) 3 (13) 3 (13) 18 (75) 8 (33) 4 (17) 4 (17) 13 (3) *t Test or X2 test. During the treatment period, the infants who received dexamethasone needed significantly less supplemental oxygen (table 2) . There were also reductions in other ventilatory settings. tion at the age of 28 days of grade 4 intraventricular haemorrhage and periventricular leucomalacia. These two infants were ventilator dependent until death. Weight gain was similar in the two groups. Median weight at the age of 28 days was 969 g in the dexamethasone and 1002 g in the placebo group. Table 4 summarises the long term outcome by the age of 1 year. There were two late deaths. One boy in the dexamethasone group died at the age of 125 days of bleeding after craniosynostosis surgery, two weeks after weaning from the respirator, and still receiving supplemental oxygen. A girl in the placebo group died at the age of 34 days of necrotising enterocolitis and sepsis; she was ventilator dependent until death. The overall mortality rate was 9-/8%. There was no significant difference in the mortality between the groups (5 9% in the dexamethasone and 12-5% in the placebo group). Even though the primary cause of death was different, all the infants who died had bronchopulmonary dysplasia.
The other measures of long term outcome were not significantly different between the dexamethasone and placebo groups except that female infants treated with dexamethasone needed a shorter time of supplemental oxygen (p=0.047). After 28 days of age dexamethasone was given to six (35°/o) infants in the dexamethasone and to eight (33%/o) infants in the placebo group. The duration of hospital stay in survivors was similar in the two g dexamethasone group the mediar hospital stay was 109 days and ir group 114 days. With one excepti vors were weaned from supplemen (8) 2 (8) 1 year of age. Three infants in the dexamethasone and one infant in the placebo group needed cryotherapy for retinopathy of prematurity. Before entry into the study basal and stimulated cortisol concentrations and A cortisol were similar in the dexamethasone and placebo group (table 5) . After the one week treatment period basal and stimulated cortisol concentrations were significantly lower in the dexamethasone than in the placebo group. At the age of 28 days there was no difference in the basal cortisol concentrations between the groups, but the stimulated cortisol and A cortisol were still significantly lower in the dexamethasone group.
Complications occurred after study entry in both groups (table 6). The incidence of sepsis and hyperglycaemia was similar, but hypertension developed significantly more often in the dexamethasone group (p=0-01). The blood pressure became normal in all infants after the treatment period and none needed treatment for hypertension at discharge. Perforation of the colon, caused by necrotising enterocolitis, occurred in two infants in the placebo group.
;roups; in the Discussion n duration of We did not succeed in enrolling the projected a the placebo number of patients for our trial. To assess ion the survi-whether this was due to changes in the compotal oxygen by sition of the patient material, we reviewed the statistics of the Children's Hospital, University of Helsinki, which is the largest of the participating units. Previous small scale studies have suggested that the respiratory status of infants treated with dexamethasone, compared with control infants, improves in the short term, allowing earlier weaning from the respirator and thus shortening the duration of mechanical ventilation.45 78 In one study, neurodevelopmental outcome at one year appeared better in infants receiving a 42 day course of dexamethasone6 but this and all other studies did not show any improvement in the long term outcome in terms of mortality, length of stay in hospital or oxygen requirement, or incidence of serious complications.
At least two factors may account for the lack of observable effects of steroids in the long term. Firstly, in most studies steroid treatment was allowed and commonly given after the trial period. This would tend to dilute possible initial differences between treatment groups. For example, in the largest study reported,9 only 47% of infants in the placebo group did not receive any steroids. In our study, 67% of the placebo group were not treated with dexamethasone after the age of 28 days, though this would have been permissible.
The second factor is the timing of steroid treatment. Based on previous clinical experience, we chose to begin dexamethasone treatment depending on the situation at 10 days of age, which is earlier than in any other reported study. Our plan to administer a high dose, 05 mg/kg/day, of dexamethasone for seven days was based on the expectation of achieving short term improvement sufficient for weaning from the respirator without causing adrenal suppression necessitating long term substitution treatment. Considering the evolution of bronchopulmonary dysplasia, with progressive fibrosis and pulmonary hypertension, it is probably unreasonable to expect much from treatment started late in the process. This may have been the problem in some previous studies. As shown in table 3, very few infants in either group survived without developing bronchopulmonary dysplasia. It seems that dependency on ventilator treatment at the age of 10 days is practically synonymous with chronic lung disease, and that dexamethasone or any other treatment started at that age cannot be considered prophylactic. If true prevention is the aim, earlier measures would be necessary. One report even suggests that glucocorticoids given in the first days of life may have a beneficial effect on the pulmonary outcome of respiratory distress syndrome.16
In general, our results are in line with those of others in that some benefit was demonstrable in the short term, but not in the long term. Long term benefits were seen only in female infants, but the small number of patients studied renders the conclusion tentative. In view of the well known effect of sex on the overall and respiratory distress syndrome mortality of VLBW infants, ' 
